靶向miRNAs防治心肌梗死后心室重构的研究进展  

Research progress of targeting miRNAs in prevention and treatment of ventricular remodeling after myocardial infarction

作　　者：丁芮 黄金玲[1] DING Rui;HUANG Jin-ling(College of Integrated Chinese and Western Medicine,Anhui University of Chinese Medicine,Institute of Integrated Traditional Chinese and Western Medicine,Anhui Academy of Chinese Medicine,Anhui Province Key Laboratory of Chinese Medicinal Formula,Hefei 230012,China)

机构地区：[1]安徽中医药大学中西医结合学院,安徽省中医药科学院中西医结合研究所,中药复方安徽省重点实验室,安徽合肥230012

出　　处：《中国药理学通报》2023年第6期1023-1029,共7页Chinese Pharmacological Bulletin

基　　金：国家自然科学基金资助项目(No 30973707,81373533,81973844);安徽省重点研究和开发计划资助项目(No 201904a07020109)。

摘　　要：心肌梗死是世界范围内的主要死亡原因之一,出现在动脉粥样硬化斑块进展和不稳定破裂的终点。心肌梗死后细胞信号受损,导致适应性不良改变,诱发心室重构和心力衰竭。微RNA(microRNAs,miRNAs)是一种负向调节基因表达的非编码小RNA,通过改变靶向mRNA的稳定性,调节蛋白质合成速率。该文综述了miRNAs参与动脉粥样硬化斑块进展、梗死期间心脏损伤和随后重构的分子机制的最新研究进展,以及临床研究的结果,并提出靶向miRNAs治疗心肌梗死和心室重构等心血管疾病进一步发展需要解决的问题及局限性。Myocardial infarction is one of the leading causes of death worldwide,appearing at the last point of atherosclerotic plaque progression and unstable rupture.Impaired cellular signals after myocardial infarction leads to maladaptive changes,leading to ventricular remodeling and heart failure.MicroRNAs(miRNAs/miRs)are a kind of non-coding small RNAs that negatively regulate gene expression and regulate protein synthesis rate by changing the stability of targeted mRNA.This article reviews the latest research progress on the involvement of miRNAs in the progression of atherosclerotic plaques,the molecular mechanism of cardiac injury and subsequent remodeling during infarction,as well as the results of clinical studies,and puts forward the problems and limitations of targeted miRNAs in the treatment of cardiovascular diseases such as myocardial infarction and ventricular remodeling.

关 键 词：MIRNAS 心肌梗死 心室重构 动脉粥样硬化 分子机制 研究进展 

分 类 号：R-05[医药卫生] R342.2R542.22R543.5